Stay updated with breaking news from Poster Area. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function ---- WU-NK-101 demonstrated robust anti-tumor activity, tumor trafficking, and penetration further augmented by monoclonal antibo...
-- WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function -- --
HMBD-001 is a proprietary anti-HER3 antibody in an ongoing Phase 1 trial targeting multiple solid tumors HMBD-001 has the potential to fully block...
/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced...
iCRO: scientific poster presentation on Sep 10, 2022: "Challenges to Assess Bone Metastases in Blinded Independent Central Review (BICR) of Breast Cancer Trials Using RECIST 1.1" iBiopsy: